NCT06691321 Caspofungin for Pneumocystis Pneumonia in PLWHIV.

Trial Parameters

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Pneumocystis jirovecii pneumonia is a significant concern in peaple with HIV/AIDS, often severe and potentially fatal. While trimethoprim/sulfamethoxazole remains the primary treatment, safety concerns exist with alternative options. Research on Pneumocystis jirovecii's beta-D glucan composition has prompted investigations into echinocandins like caspofungin, showing promise in murine models and some positive results in human studies. Evaluating caspofungin's efficacy through observational studies is crucial due to safety advantages over current treatments and limited documented data.

Eligibility Criteria

Inclusion Criteria: * Diagnosis of probable or proven PCP, according to its diagnostic classification (refer to classification at the end of this section). * Have clinical laboratory and virological diagnostic laboratory studies at the time of admission. * Classification criteria for Pneumonia by P. jirovecii according to Robert-Gangneux et al.: Proven: Confirmation by pathology or microbiology. Possible: Presence of three out of four clinical or radiological criteria. Probable: Presence of one clinical or radiological criterion without another identified microorganism. Exclusion Criteria: * With a treatment switch to caspofungin after day 7 of treatment initiation (applies only to group B). * Patients who have developed an additional opportunistic lung infection during their hospitalization, other than cytomegalovirus pneumonitis or SARS-CoV-2 pneumonia.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.